Vertex Pharmaceuticals

Ultime notizie

Titoli nella lingua originale della fonte.

• Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks (si apre in una nuova scheda)

  Yahoo Finance · 1 ott 2026

• Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know (si apre in una nuova scheda)

  Yahoo Finance · 1 ott 2026

• Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors (si apre in una nuova scheda)

  marketwatch.com · 1 ott 2026

• Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? (si apre in una nuova scheda)

  The Motley Fool · 1 ott 2026

• VRTX drops as $10B Crinetics Pharmaceuticals acquisition raises risk (si apre in una nuova scheda)

  Traders Union · 1 ott 2026

• Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know (si apre in una nuova scheda)

  TradingKey · 1 ott 2026

• M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy (si apre in una nuova scheda)

  biospace.com · 1 ott 2026

• Vertex Pharmaceuticals And 2 Other Top Biotech Stocks To Own (si apre in una nuova scheda)

  Simply Wall Street · 30 set 2026

• Vertex Pharmaceuticals stock holds at EUR 464.53 as UBS lifts target (si apre in una nuova scheda)

  AD HOC NEWS · 30 set 2026

• Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade (si apre in una nuova scheda)

  Seeking Alpha · 29 set 2026

• Vertex Pharmaceuticals price target raised to $615 from $585 at UBS (si apre in una nuova scheda)

  TipRanks · 29 set 2026

• 2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. (si apre in una nuova scheda)

  The Motley Fool · 29 set 2026

• Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? (si apre in una nuova scheda)

  Insider Monkey · 29 set 2026

• Vertex Pharmaceuticals stock last trades at USD 526.66 on September 28, 2026 (si apre in una nuova scheda)

  AD HOC NEWS · 28 set 2026

• Vertex Pharmaceuticals Price Target Raised to $615.00/Share From $585.00 by UBS (si apre in una nuova scheda)

  Moomoo · 28 set 2026

• Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts (si apre in una nuova scheda)

  Yahoo Finance · 28 set 2026

• Vertex Pharmaceuticals rises on strong cystic f... (si apre in una nuova scheda)

  Pluang · 28 set 2026

• VERTEX PHARMACEUTICALS INCORPORATED : UBS RAISES TARGET PRICE TO $615 FROM $585 (si apre in una nuova scheda)

  bitget.com · 28 set 2026

• UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating (si apre in una nuova scheda)

  Moomoo · 28 set 2026

• 2 Healthcare Stocks to Target This Week and 1 We Avoid (si apre in una nuova scheda)

  StockStory · 28 set 2026

• Vertex Pharmaceuticals stock draws attention after kidney data (si apre in una nuova scheda)

  AD HOC NEWS · 28 set 2026

• Vertex Pharmaceuticals (NasdaqGS:VRTX) Stock Forecast & Analyst Predictions (si apre in una nuova scheda)

  Simply Wall Street · 28 set 2026

• Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (si apre in una nuova scheda)

  Eastern Progress · 28 set 2026

• Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript (si apre in una nuova scheda)

  fortune.com · 26 set 2026

• 2 Healthcare Stocks That Just Delivered Great News for Investors (si apre in una nuova scheda)

  Motley Fool · 26 set 2026

• Kidney Drug Study Progress Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) (si apre in una nuova scheda)

  Simply Wall Street · 25 set 2026

• Vertex Pharmaceuticals Inc (CEUX:VX1d) Stock Price & 30 Year Financial Data (si apre in una nuova scheda)

  GuruFocus · 25 set 2026

• Vertex Pharmaceuticals Inc (CEUX:VX1d) Insider Trading Activity | Apple Insider Buys and Sells (si apre in una nuova scheda)

  GuruFocus · 25 set 2026

• Press Release Service: Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia (si apre in una nuova scheda)

  CRISPR Medicine News · 25 set 2026

• Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? (si apre in una nuova scheda)

  Simply Wall St. · 25 set 2026